Processa Pharmaceuticals, Inc.

NasdaqCM:PCSA Rapporto sulle azioni

Cap. di mercato: US$3.7m

Processa Pharmaceuticals Performance dei guadagni passati

Il passato criteri di controllo 0/6

Processa Pharmaceuticals's earnings have been declining at an average annual rate of -14.4%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually.

Informazioni chiave

-14.4%

Tasso di crescita degli utili

11.5%

Tasso di crescita dell'EPS

Pharmaceuticals Crescita del settore6.0%
Tasso di crescita dei ricavin/a
Rendimento del capitale proprio-309.8%
Margine netton/a
Ultimo aggiornamento sui guadagni30 Sep 2024

Aggiornamenti sulle prestazioni recenti

Nessun aggiornamento

Recent updates

We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

Dec 12
We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

Will Processa Pharmaceuticals (NASDAQ:PCSA) Spend Its Cash Wisely?

Oct 20
Will Processa Pharmaceuticals (NASDAQ:PCSA) Spend Its Cash Wisely?

Processa Pharmaceuticals GAAP EPS of $0.53 beats by $0.73

Aug 12

We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

Jul 07
We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

We're Not Very Worried About Processa Pharmaceuticals' (NASDAQ:PCSA) Cash Burn Rate

Jan 20
We're Not Very Worried About Processa Pharmaceuticals' (NASDAQ:PCSA) Cash Burn Rate

Processa Pharmaceuticals (NASDAQ:PCSA) Is In A Good Position To Deliver On Growth Plans

Aug 26
Processa Pharmaceuticals (NASDAQ:PCSA) Is In A Good Position To Deliver On Growth Plans

Processa Pharmaceuticals (PCSA) Presents At LD Micro Invitations XI Virtual Conference - Slideshow

Jun 15

What Percentage Of Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Do Insiders Own?

Mar 15
What Percentage Of Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Do Insiders Own?

Processa Pharmaceuticals: Multiple Shots On Goal With Total TAM Of $8B - Worth A Look

Jan 29

How Many Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Did Insiders Buy, In The Last Year?

Jan 20
How Many Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Did Insiders Buy, In The Last Year?

Ripartizione dei ricavi e delle spese

Come Processa Pharmaceuticals guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.


Storia dei guadagni e delle entrate

NasdaqCM:PCSA Ricavi, spese e utili (USD Millions )
DataRicaviGuadagniSpese G+ASpese di R&S
30 Sep 240-1257
30 Jun 240-1056
31 Mar 240-1046
31 Dec 230-1166
30 Sep 230-2278
30 Jun 230-26910
31 Mar 230-281011
31 Dec 220-27911
30 Sep 220-18710
30 Jun 220-1569
31 Mar 220-1357
31 Dec 210-1157
30 Sep 210-2357
30 Jun 210-2345
31 Mar 210-2034
31 Dec 200-1933
30 Sep 200-622
30 Jun 200-422
31 Mar 200-422
31 Dec 190-422
30 Sep 190-312
30 Jun 190-312
31 Mar 190-313
31 Dec 180-413
30 Sep 180-413
30 Jun 180-413
31 Mar 180-312
31 Dec 170-211
31 Dec 160-202

Guadagni di qualità: PCSA is currently unprofitable.

Margine di profitto in crescita: PCSA is currently unprofitable.


Flusso di cassa libero e analisi degli utili


Analisi della crescita degli utili nel passato

Andamento degli utili: PCSA is unprofitable, and losses have increased over the past 5 years at a rate of 14.4% per year.

Accelerare la crescita: Unable to compare PCSA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Guadagni vs Settore: PCSA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).


Rendimento del capitale proprio

ROE elevato: PCSA has a negative Return on Equity (-309.78%), as it is currently unprofitable.


Rendimento delle attività


Rendimento del capitale investito


Scoprire le aziende con forti performance passate